• Major milestones reached in the two phase 2/3 studies in the treatment of Stroke with glenzocimab:
– ACTISAVE study: more than 240 patients recruited to date
– GREEN study: recruitment of the first patients
• Exchanges between the University of Birmingham and the British regulatory authorities for the LIBERATE study in the treatment of myocardial infarction
• Cash of €6.6 million as of December 31, 2022
• Success of the €12.2 million capital increase in March 2023
Paris, France, March 23, 2023 – 6:15 p.m. CET – ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, including ischemic stroke, today publishes its annual results for the financial year ended December 31, 2022 and approved by the Board of Directors on March 23, 2023, and provides an update on its latest progress.
To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected]